Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 11

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 1
Chunk 11
---
, chemokines and other inflammatory molecules from recovered organs. We initially are focused on recovered kidneys from deceased
donors. We have previously demonstrated the removal of multiple viruses and exosomes and exosomal particles from buffer solutions, in
vitro, utilizing a scaled-down version of our Hemopurifier and believe this process could reduce transplantation complications by
improving graft function, reducing graft rejection, maintaining or improving organ viability prior to transplantation, and potentially
reducing the number of kidneys rejected for transplant.

Successful outcomes of
human trials will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier.
Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain
patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment
technology.

In addition to the foregoing, we are monitoring
closely the impact of inflation, the war between Russia and Ukraine and the military conflicts in Israel and the surrounding areas, as
well as related political and economic responses and counter-responses by various global factors on our business. Given the level of uncertainty
regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines
and future access to capital. The full extent to which inflation, the ongoing military conflicts and other global instability will impact
our business, results of operations, financial condition, clinical trials and preclinical research will depend on future developments,
as well as the economic impact on national and international markets that are highly uncertain.

We incorporated in Nevada on March 10, 1999. Our
executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360.
Our website address is www.aethlonmedical.com.

Our common stock is listed on the Nasdaq Capital Market under the symbol
“AEMD.”

     9 

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

During the nine months ended December 31, 2024,
there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended
March 31, 2024.

REVERSE STOCK SPLIT

On October 4, 2023, we effected